Effect of Aspirin in schizophrenia

Phase 3

Conditions: schizophrenia.
Paranoid schizophrenia

Registration Number: IRCT201109287660N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Introduction: schizophrenia is one of the most common psychological diseases. New investigations showed that NSAIDs usage could be helpful in its treatment by preventing PG sanitize with inhibiting cycloxygeniz activation. The aim of this study was to evaluate the affect of adding aspirin to regular schizophrenia treatment. Methods: in this randomized clinical trial 40 schizophrenia patients who were admitted in Ibn Sina hospital and had the inclusion criteria were entered and fallowed up for 12 weeks. First group had received 1 gram aspirin and second group had received placebo with the same shap and color add on regular treatment of schizophrenia. Patient symptoms and signs and their side effects were compared with SPSS software using mann-whittny and t-test regard to the variables. Results: patient`s mean age was 8.68± 31.9 year and 88.3 percent (33 patients) of them were male and 17.5%(7 patients) were female. Mean overall PANSS in aspirin group and placebo was 11.76±62.95 and 5.8±56.8in third week and 11.77± 60.15 and 6.63±53.8in sixth weeks and this difference were significant. (P=0.045, P=0.042) digit span and Wechsler showed no differences after intervention. (P>0.05) Conclusion: adding aspirin to regular schizophrenia treatment could be helpful to control some signs and symptoms and reduce psychopathology.

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 40

Inclusion Criteria

1 - Is based on DSM-IV diagnosis of schizophrenia. 2 - The patient or patient's guardian consent to participate. 3 - PANSS score at the beginning of the project is more than 60. 4 - less than 5 years of disease duration and between 3 to 1 episodes. 5 - No physical disease based on clinical examination. 6 - Chronic NSAID is not used. 7 - Not taking corticosteroids. 8 - Not pregnant. 9 - there is no contraindication for aspirin and omeprazole. Exclusion criteria: 1 - Sensitivity to the drug 2 - Patients who choose to be excluded. 3 – Require other drugs. (Anticholinergics and benzodiazepines are excepted) 4 – Where ECT is needed.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive disorders. Timepoint: baseline and 3th,6th,12th weeks. Method of measurement: cognition tests.;Clinical symptoms. Timepoint: baseline and 3th,6th,12th weeks. Method of measurement: PANSS.

Secondary Outcome Measures